← 返回

EBV 编码的 miR-BART12-3p 下调 GSDMB 抑制胃癌细胞中杀伤淋巴细胞介导的细胞焦亡

英文原题:Downregulation of GSDMB by EBV-encoded miR-BART12-3p suppresses killer lymphocyte-mediated pyroptosis in gastric cancer cells.

查看英文原题

Downregulation of GSDMB by EBV-encoded miR-BART12-3p suppresses killer lymphocyte-mediated pyroptosis in gastric cancer cells.

PubMed 2026/08/05(内容时间) PLoS Pathog Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

EBV相关胃癌(EBVaGC)是胃癌(GC)的一种独特亚型,具有特征性的临床病理和分子特征。EBVaGC比EBV阴性胃癌表现出更广泛的淋巴细胞浸润,并表达一系列EBV编码的病毒产物。

然而,EBV阳性GC细胞与肿瘤微环境中免疫细胞之间的相互作用尚不清楚。在此,我们发现EBV下调EBV阳性GC细胞中GSDMB——一种焦亡执行分子——的表达,并使这些细胞能够逃避NK细胞和细胞毒性T淋巴细胞所诱导的GSDMB切割依赖性焦亡。该焦亡主要通过GC细胞中的全长GSDMB异构体(GSDMBiso3)执行。

我们进一步发现,EBV编码的miR-BART12-3p靶向GSDMB 3‘-UTR以下调其在GC细胞中的表达。在体外和体内实验中均证实,抑制miR-BART12-3p可通过触发GSDMB切割诱导的焦亡,增强NK细胞对EBV阳性GC细胞的抗肿瘤效果。

总之,本研究阐明了EBV下调GSDMB以逃逸免疫细胞杀伤的分子机制,并为将基于杀伤淋巴细胞的疗法与miR-BART12-3p抑制剂联合用于治疗EBVaGC提供了理论依据。

展开英文摘要原文

Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) is a distinct subtype of gastric cancer (GC) with characteristic clinicopathological and molecular features. EBVaGC exhibits a more extensive lymphocyte infiltration than EBV-negative counterparts, and expresses a range of EBV encoded viral products.

However, the interactions between EBV-positive GC cells and immune cells within the tumor microenvironment are not well understood.

Herein we found that EBV downregulates GSDMB, an executive molecule of pyroptosis, in EBV-positive GC cells and enables these cells to escape GSDMB cleavage-induced pyroptosis by NK cells and cytotoxic T lymphocytes. The pyroptosis is mainly executed through the full length GSDMB isoform (GSDMBiso3) in GC cells.

We further found EBV-encoded miR-BART12-3p targets the GSDMB 3'-UTR to downregulate its expression in GC cells. Inhibition of miR-BART12-3p enhances antitumor efficacy of NK cells against EBV-positive GC cells by triggering GSDMB cleavage-induced pyroptosis, as demonstrated both in vitro and in vivo.

In conclusion, this study elucidates the molecular mechanism by which EBV downregulates GSDMB to evade immune cell killing, and provides a rationale for combining killer lymphocyte-based therapies with a miR-BART12-3p inhibitor for the treatment of EBVaGC.

论文信息

作者
Xu M、Hao S、Huang S、Liu J、Lin J、Zhang J、Qin Q
单位
Laboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.China
文献类型
非美国政府资助研究
期刊
PLoS pathogens2026 Aug
原文标识
PubMed 42555663 · DOI 10.1371/journal.ppat.1014495